Research provides new evidence for potential blood-based biomarker for Alzheimer's

A potential blood-based biomarker for Alzheimer's and other neurodegenerative diseases seems even more promising thanks to new research from a Massachusetts General Hospital-led study. According to this team's work, neurofilament light chain (NfL) has great potential as a biomarker for early detection of Alzheimer's disease and could be also useful for monitoring treatment response for that condition.

"We wanted to determine the earliest age at which plasma NfL levels could distinguish individuals at high risk of Alzheimer's," says Quiroz, who is also an MGH Research Scholar 2020-2025.

They found that NfL levels increased with age among people at genetic risk because of a specific mutation (PSEN1 E280A) and began to differentiate carriers from non-carriers at age 22, an average of 22 years before their estimated age of cognitive impairment (age 44).

Neurofilament light chain (NfL) is a biomarker of neurodegeneration - damage to neurons. Measures of NfL concentrations in cerebral spinal fluid (CSF) and blood have been used to detect and track neurodegeneration in individuals with Alzheimer's disease and other brain disorders.

The team used an ultra-sensitive single molecule array immunoassay to measure NfL concentrations in serum and plasma. Earlier studies have shown close correlations between blood-based and CSF measurements in people and animal models of neurodegenerative diseases.

The team studied over 2,000 members of the world's largest kindred with familial Alzheimer's because of a single mutation (PSEN1 E280A) --the familial Alzheimer's disease Colombian kindred, which were aged 8-75 years and had no other neurological or health conditions.

Next they used a single molecule array immunoassay to examine the relationship between plasma NfL concentrations and age to establish the earliest age at which NfL concentrations start to diverge between mutation carriers and non-carriers. The team enrolled 1070 PSEN1 E280A mutation carriers and 1074 non-carriers with baseline assessments.

Plasma NfL measurements increased with age in both groups (p<0 -="" 22="" 44="" ability="" age="" and="" at="" began="" between="" carriers="" clinical="" close="" cognitive="" differentiate="" discriminate="" estimated="" font="" from="" high="" impairment="" is="" median="" mild="" nfl="" non-carriers="" of="" only="" onset.="" onset="" plasma="" reached="" sensitivity="" the="" to="" years.="" years="">

Our findings add to the growing evidence that blood-based NfL can be useful in detecting neurodegeneration, starting with very early, subtle elevations way before the onset of clinical symptoms. We need more studies to further explore NfL as a way to inform prognosis and evaluate treatments in Alzheimer's disease."

Yakeel T. Quiroz, PhD, Assistant Professor at Harvard Medical School, and Director of the Familial Dementia Neuroimaging Lab at Massachusetts General Hospital

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.     

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement

Blood test detects Alzheimer's 16 years before symptoms begin

A simple blood test could predict if a patient will develop Alzheimer's disease up to 16 years before symptoms begin, a new study finds.

By measuring changes in the levels of a protein in the blood, called neurofilament light chain (NfL), researchers believe any rise in levels of the protein could be an early sign of the disease, according to the study published recently.

 

NfL is a "marker in the blood which gives an indication of nerve cell loss in the brain," explained lead researcher, professor of cell biology of neurological diseases. ''The more neurofilament you have in the blood, the more brain damage you have," he said.

 

There is still no effective treatment for Alzheimer's, but the Prof. thinks the new blood test will be "very important for clinical studies." He hopes the test will allow researchers to monitor the effectiveness of new treatments before people have started to experience symptoms, by measuring how levels of the protein are affected.

 

"Alzheimer's disease starts at least a decade, maybe even 20 years, before we have any symptoms," said the Prof.

 

There is currently no test doctors can use to conclusively determine whether someone will get Alzheimer's disease and there are a lot of unknowns about its cause. One widely believed theory is that the disease is driven by the production and deposition of beta-amyloid plaques between neurons in the brain. 

 

In the UK, there are 850,000 people living with dementia, Alzheimer's disease is the most common type of this condition, according to the Alzheimer's Society in the UK. According to the US Centers for Disease Control and Prevention, as many as 5 million Americans have Alzheimer's disease.

 

Of the many changes in the brain which precede the disease's symptoms, one change is also the accumulation of NfL in the blood before any symptoms begin, said the Prof.

 

Researchers measured the rate of change in NfL using a blood test in 405 individuals from across the world enrolled in the Dominantly Inherited Alzheimer's Network -- an international research effort focused on dominantly inherited Alzheimer's disease, a rare form of the illness that represents less than 1% of all cases of Alzheimer's, according to the researchers.

 

The team measured NfL protein levels in the participants through blood samples, brain imaging and cognitive tests on average every two and half years over the last seven years. The study is ongoing.

The patients carrying the gene mutations predisposing them to Alzheimer's disease -- a group of 243 -- were found to have increasing levels of NfL compared to the control group, consisting of 162 family members without the mutation. 

 

By measuring the protein, the Prof. said "we can measure with our blood test the changes in the brain many, many years before we have the symptoms." So far, 13 participants had developed Alzheimer's.

 

Through the cognitive testing and brain imaging, NfL levels were shown to be correlated with cognitive decline and brain shrinkage, said the Prof. Researchers also found an association between 39 participants' changing NfL levels and brain loss and cognitive decline after two years.

 

The findings come together to show that changes in NfL levels were an accurate predictor of how brain damage develops, according to the study. 

 

The Prof. likened his team's work to the cancer field. "In general this is not something new," he explained, as certain markers, for example, tell people they have cancer even when there are no symptoms of the disease. The test is already commercially available; it detects NfL in cerebrospinal fluid for measurement of different neurological conditions, and the Prof. is confident that future clinical trials for new Alzheimer's drugs will include the marker his team developed.

 

But the Prof. warns that the test is not specific to Alzheimer's disease, he added. Higher levels of neurofilament indicate brain damage, but this can also be due to brain injury from an accident, for example.

 

This is not the first blood test developed in hope of diagnosing the disease early.

 

Previous research has shown options for detecting Alzheimer's disease in its early stages. A 2018 study examined the presence and levels of amyloid beta in a person's brain by looking at people with varying levels of health, including some with who were healthy, some who had mild cognitive impairments and some who had Alzheimer's disease.

 

In 2014, using a blood test that looked at 10 specific lipids in people's blood, researchers were also able to predict Alzheimer's before symptoms appeared.

 

A postdoctoral researcher said that the researchers "most promisingly" show changes of NfL predicting cognitive test results and thinning of the cortex, "two main symptoms of Alzheimer's Disease." 

 

THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.                                    PS- THOSE INTERESTED IN RECIPES ARE FREE TO  VIEW MY BLOG-                                                                                           https://gseasyrecipes.blogspot.com/       
                                                                                                                                                                      FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG-                                                  https:// kneereplacement-stickclub.blogspot.com/           
                                                                           FOR CROCHET DESIGNS                                                                                                                                                                                                  https://gscrochetdesigns.blogspot.com